NQWM
ABBV icon

Northwest Quadrant Wealth Management’s AbbVie ABBV Stock Holding History

Northwest Quadrant Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$426K Buy
1,960
+12
+0.6% +$2.66K 0.09% 35
2025
Q4 		$445K Buy
1,948
+11
+0.6% +$2.51K 0.09% 37
2025
Q3 		$448K Buy
1,937
+92
+5% +$18.7K 0.09% 38
2025
Q2 		$342K Buy
1,845
+13
+0.7% +$2.42K 0.08% 43
2025
Q1 		$384K Sell
1,832
-46
-2% -$8.94K 0.09% 37
2024
Q4 		$334K Buy
1,878
+13
+0.7% +$2.39K 0.08% 48
2024
Q3 		$368K Buy
1,865
+11
+0.6% +$2.05K 0.08% 40
2024
Q2 		$318K Buy
1,854
+14
+0.8% +$2.32K 0.08% 40
2024
Q1 		$335K Buy
1,840
+12
+0.7% +$2.07K 0.08% 44
2023
Q4 		$283K Buy
1,828
+182
+11% +$26.5K 0.07% 47
2023
Q3 		$245K Buy
1,646
+13
+0.8% +$1.91K 0.07% 50
2023
Q2 		$220K Buy
1,633
+12
+0.7% +$1.76K 0.06% 53
2023
Q1 		$258K Buy
1,621
+11
+0.7% +$1.68K 0.07% 48
2022
Q4 		$260K Sell
1,610
-73
-4% -$11.2K 0.08% 50
2022
Q3 		$226K Buy
1,683
+53
+3% +$7.61K 0.07% 49
2022
Q2 		$251K Sell
1,630
-291
-15% -$44.5K 0.08% 52
2022
Q1 		$311K Sell
1,921
-123
-6% -$17.9K 0.09% 45
2021
Q4 		$277K Buy
2,044
+12
+0.6% +$1.42K 0.07% 50
2021
Q3 		$221K Buy
2,032
+97
+5% +$11.1K 0.06% 62
2021
Q2 		$217K Buy
1,935
+12
+0.6% +$1.35K 0.06% 63
2021
Q1 		$208K Buy
1,923
+13
+0.7% +$1.39K 0.06% 61
2020
Q4 		$201K Buy
+1,910
New +$184K 0.07% 60
2020
Q3 		– Sell
-2,185
Closed -$211K – 56
2020
Q2 		$211K Sell
2,185
-186
-8% -$16.4K 0.09% 54
2020
Q1 		$200K Buy
2,371
+15
+0.6% +$1.28K 0.09% 54
2019
Q4 		$209K Buy
+2,356
New +$196K 0.09% 66
2019
Q2 		– Sell
-2,652
Closed -$214K – 63
2019
Q1 		$214K Buy
2,652
+7
+0.3% +$573 0.1% 58
2018
Q4 		$204K Buy
2,645
+68
+3% +$5.98K 0.1% 57
2018
Q3 		$226K Buy
2,577
+302
+13% +$28.6K 0.14% 47
2018
Q2 		$211K Buy
+2,275
New +$222K 0.14% 51

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northwest Quadrant Wealth Management's ABBV Position: Q1 2026 in Review

Northwest Quadrant Wealth Management increased its AbbVie (ABBV) stake by 0.62% in Q1 2026, buying an estimated $2.66K and bringing the position to 1,960 shares worth $426K. The position accounts for 0.09% of the portfolio, ranked #35.

Northwest Quadrant Wealth Management first reported a position in ABBV in Q2 2018 and has held it in 29 quarters since. The position peaked at $448K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Northwest Quadrant Wealth Management held 1,960 shares of AbbVie worth $426K as of Q1 2026.
  • Northwest Quadrant Wealth Management bought 12 AbbVie shares in Q1 2026, an estimated $2.66K.
  • AbbVie made up 0.09% of Northwest Quadrant Wealth Management's portfolio in Q1 2026, its #35 holding.
  • Northwest Quadrant Wealth Management first reported a position in AbbVie in Q2 2018 and has held it in 29 quarters since.
  • Northwest Quadrant Wealth Management's AbbVie position peaked at $448K in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Northwest Quadrant Wealth Management's 13F filing for Q1 2026, filed 11 May 2026.